title: [Atomoxetine for treatment of children and adolescents with ADHD].
abstract: Atomoxetine reduces ADHD symptoms in children and adolescents significantly and is indicated for ADHD with co-morbid anxiety, depression and tics or with an increased risk of abuse. Number needed to treat is 3.4-5. Common adverse effects are stomach pain, decreased appetite and somnolence. Serious adverse effects include increased vascular tone, decreased growth rate and increased suicidal behaviour. In most cases adverse effects are mild to moderate and transient. Since atomoxetine was launched in 2006, 117 cases of toxic exposures have been reported in Denmark.
authors.affiliation: Poppelgade 11, 3. tv., 2200 København N. katarina@resen.org.
authors.forename: Katarina
authors.initials: K
authors.lastname: Resen
authors.forename: Anne Katrine
authors.initials: AK
authors.lastname: Pagsberg
authors.forename: Gesche
authors.initials: G
authors.lastname: Jörgens
mesh_terms: D000293:Adolescent; D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D002648:Child; D006801:Humans
chemical_list: D018759:Adrenergic Uptake Inhibitors; D000069445:Atomoxetine Hydrochloride